The EPO activity was significantly decreased in three treated asthma (Co-Q10 treated asthma: 0.18 ± 0.02, Co-Q10, O-3 treated asthma: 0.16 ± 0.01, Co-Q10, Mg-S treated asthma: 0.16 ± 0.02) and rhinitis (Co-Q10 treated rhinitis: 0.13 ± 0.02, Co-Q10, O-3 treated rhinitis: 0.13 ± 0.02, Co-Q10, Mg-S treated rhinitis: 0.16 ± 0.01) groups compared to non-treated asthma (0.33 ± 0.03) and non-treated rhinitis groups (0.24 ± 0.01) (Fig. 7) (P < 0.05). The gene discussed is EPO; the disease is rhinitis.